A New Kind of Diabetes Drug


By: Linda von Wartburg

Both Bristol-Myers Squibb and GlaxoSmithKline are developing new drugs that block the re-absorption of excess glucose by the kidneys, allowing it to be excreted by the body instead.

The new drugs, called sodium glucose uptake transporter 2 inhibitors (SGLT-2), go by the names of dapagliflozin and sergliflozin, respectively. A few preliminary studies have shown that they led to improved glucose levels in patients.

* * *

Source: ADA



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.